Highlight
Obicetrapib, a potent and selective cholesteryl ester transfer protein (CETP) inhibitor, reduces LDL cholesterol by approximately 30% in patients with high cardiovascular risk already on maximal lipid-lowering therapy. This multinational, randomized, placebo-controlled trial demonstrated significant LDL cholesterol reduction with a safety profile similar to placebo. These findings suggest obicetrapib could become an important adjunct therapy for patients with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD).
Study Background and Disease Burden
Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, largely driven by elevated low-density lipoprotein (LDL) cholesterol levels. Despite advances in lipid-lowering therapies, including statins and PCSK9 inhibitors, many high-risk patients fail to achieve optimal LDL cholesterol targets, particularly those with heterozygous familial hypercholesterolemia or recurrent ASCVD. Cholesteryl ester transfer protein (CETP) inhibitors represent a mechanistically distinct approach to lipid modification by enhancing reverse cholesterol transport and reducing LDL cholesterol levels.
Obicetrapib is a novel, highly selective CETP inhibitor under investigation for its lipid-modulating properties. While previous CETP inhibitors had mixed cardiovascular outcome data and safety concerns, obicetrapib’s efficacy and safety profile had not been fully established in high-risk populations on maximal lipid-lowering therapy. This trial aimed to address this critical unmet need.
Study Design
The BROADWAY trial was a multinational, randomized, double-blind, placebo-controlled study enrolling 2,530 participants with either heterozygous familial hypercholesterolemia or a history of ASCVD. Inclusion criteria required participants to be on the maximum tolerated doses of lipid-lowering therapies, with LDL cholesterol ≥100 mg/dL or non-HDL cholesterol ≥130 mg/dL, or LDL cholesterol between 55–100 mg/dL or non-HDL cholesterol between 85–130 mg/dL with at least one additional cardiovascular risk factor.
Participants were randomized in a 2:1 ratio to receive obicetrapib at 10 mg once daily or placebo for 365 days. The primary endpoint was the percent change in LDL cholesterol from baseline to day 84. Secondary endpoints included safety assessments, other lipid parameters, and longer-term lipid changes.
Key Findings
Among the 2,530 randomized patients, the mean age was 65 years, with 34% women, and a mean baseline LDL cholesterol of 98 mg/dL. The obicetrapib group demonstrated a least-squares mean percent LDL cholesterol reduction of 29.9% (95% CI, -32.1 to -27.8) at day 84 compared with an increase of 2.7% (95% CI, -0.4 to 5.8) in the placebo group. The between-group difference was a highly significant -32.6 percentage points (95% CI, -35.8 to -29.5; P<0.001).
Beyond LDL cholesterol, obicetrapib showed favorable effects on other atherogenic lipoproteins including non-HDL cholesterol and apolipoprotein B reductions, consistent with comprehensive lipid improvement. Importantly, the incidence of adverse events was similar between the treatment and placebo arms, supporting a good safety and tolerability profile over the study duration.
These results demonstrate that obicetrapib provides substantial additional LDL cholesterol reduction on top of maximal standard therapy in patients at very high cardiovascular risk, potentially translating into reduced residual cardiovascular risk.
Expert Commentary
Experts herald obicetrapib’s potent LDL-lowering capacity as a significant advancement in lipid management, especially for patients inadequately controlled despite current standards of care. Dr. Steven J. Nicholls, the principal investigator, highlights that “obicetrapib’s effect on LDL-C reduction is robust and achieved without safety signals, positioning it as a promising therapeutic option for high-risk patients with unmet needs.”
Previous CETP inhibitors faced setbacks due to off-target effects or insufficient cardiovascular event data. However, obicetrapib’s selective mechanism and encouraging safety data rekindle interest in this drug class. The BROADWAY trial’s enrolment of patients on maximal therapy, including statins, acknowledges the real-world complexity of lipid management and bolsters the generalizability of findings.
Limitations include the primary focus on lipid endpoints without reported hard cardiovascular outcomes, necessitating future outcome trials to confirm event reduction. Longer-term safety and effectiveness will also require continued surveillance.
Conclusion
The BROADWAY trial establishes obicetrapib as an effective and safe CETP inhibitor capable of lowering LDL cholesterol by nearly 30% in patients with heterozygous familial hypercholesterolemia or ASCVD already on optimized lipid-lowering therapy. This new agent may address residual cardiovascular risk in a high-risk population inadequately managed by existing therapies.
Future research should focus on cardiovascular outcomes, long-term safety, and comparative effectiveness against other novel agents. Clinicians should remain attentive to emerging data as obicetrapib progresses through clinical development, potentially enriching the lipid-modifying armamentarium and enhancing cardiovascular risk reduction strategies.
References
Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular Risk. N Engl J Med. 2025 Jul 3;393(1):51-61. doi:10.1056/NEJMoa2415820. Epub 2025 May 7. PMID: 40337982.
Kastelein JJP, et al. Cholesteryl Ester Transfer Protein Inhibition and Cardiovascular Outcomes: The CETP Inhibitor Story. Circulation. 2024;149(5):324-337.
Robinson JG. Lipid-Lowering Therapy Beyond Statins: A Review of New Therapies and Emerging Targets. J Am Coll Cardiol. 2023;82(7):617-631.